Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world Polatuzumab Vedotin in aggressive B-cell NHL (China)
ChiCTR2500107582Phase 4Recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Aug 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of polatuzumab vedotin in non-Hodgkin lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL) and 6 more (2 arms), sponsored by Henan Cancer Hospital. Primary endpoint: Objective Response Rate. Started Aug 2025; status: recruiting.
02
Drugs
polatuzumab vedotin
03
Conditions
non-Hodgkin lymphoma (NHL)diffuse large B-cell lymphoma (DLBCL)primary mediastinal large B-cell lymphoma (PMBCL)primary central nervous system lymphoma (PCNSL)follicular lymphoma (FL)
Beyond the preview
Go deeper on ChiCTR2500107582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500107582.